Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Antengene, Ardelyx, Ascletis, Astrazeneca, Beigene, Brexogen, Brim, Eccogene, Eisai, Kyowa Kirin, Moderna, Shanghai Henlius.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Astellas, Biocytogen, Cynata, DKSH Holding, Eisai, Eucure, Intas, Isu Abaxis, Kinarus, Laboratorio Reig Jofre, Leanbio, Memo, Mitobridge, Ono, Orsobio, Shionogi, Syna, TFF.
CSL Ltd. subsidiary CSL Seqirus signed a licensing and development deal with Arcturus Therapeutics Inc. to in-license Arcturus’ late-stage self-amplifying mRNA vaccine platform technology. Arcturus will receive $200 million up front and is eligible to receive more than $1.3 billion in development milestones and over $3 billion in commercial milestones.
Zhuhai Beihai Biotech Co. Ltd. has raised nearly ¥200 million (US$27.5 million) in a series B round slated to support clinical trials for its lead candidates as well as preparations to file an NDA for its core asset, BH-009.
New research presented by the University of Michigan revealed groundbreaking results for Certa Therapeutics Pty Ltd.’s lead candidate, FT-011, for serious inflammatory and fibrotic diseases.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Akeso, Astrazeneca, Biontech, Carsgen, GSK, Kira, Moderna, Novavax, Pfizer, Roche, Telix, Zhiyu.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Epivax, Intravacc, JW, Kissei, Obseva, SK.
RSS
